Related Experiment Video
Updated: Jan 22, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Immunotherapy in Esophagogastric Adenocarcinoma
Alexander Stein1, Peter Thuss-Patience2
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract:
Immunotherapy, particular PD-1/L1 inhibition, is a relevant treatment approach in esophagogastric adenocarcinoma. To date, single-agent activity is limited to the chemotherapy refractory setting and molecularly defined subgroups. Currently, ongoing trials, which are likely to relevantly change the landscape of treatment for this disease in the next years, evaluate different combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. The German AIO study group has launched several combination trials in the perioperative, first-line, and advanced disease setting to further define the role of immunotherapy in esophagogastric adenocarcinoma.
Insights
Immunotherapy, such as PD-1/L1 inhibitors, shows promise for esophagogastric adenocarcinoma. Ongoing trials are exploring combinations with chemotherapy and targeted agents to improve treatment outcomes.
Area of Science:
- Gastroenterology and Oncology
- Immunotherapy research
- Esophagogastric adenocarcinoma treatment
Background:
- Immunotherapy, specifically PD-1/L1 inhibition, is an emerging treatment for esophagogastric adenocarcinoma.
- Current single-agent immunotherapy efficacy is restricted to chemotherapy-refractory patients and specific molecular subgroups.
- Significant treatment landscape changes are anticipated due to ongoing clinical trials.
Purpose of the Study:
- To review the current role and future directions of immunotherapy in esophagogastric adenocarcinoma.
- To highlight ongoing combination trials evaluating immunotherapy with chemotherapy and targeted agents.
- To underscore the German AIO study group's contributions to advancing immunotherapy research in this disease.
Main Methods:
- Review of current clinical trial data and literature on immunotherapy in esophagogastric adenocarcinoma.
- Analysis of ongoing and planned combination studies by the German AIO study group.
- Focus on different disease settings: perioperative, first-line, and advanced disease.
Main Results:
- Single-agent immunotherapy activity is currently limited.
- Combination strategies are under investigation across various treatment settings.
- Several trials are actively defining the future role of immunotherapy.
Conclusions:
- Combination immunotherapy approaches hold significant potential to alter treatment paradigms for esophagogastric adenocarcinoma.
- Further research and clinical trials are crucial to optimize immunotherapy use.
- The German AIO study group is actively contributing to this research.
